The pharmacokinetics of 3-hydroxy-5-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin (KRM-1648) in rats and dogs given a single oral dose of 3, 30, or 100 mg/kg of body weight were studied. In the rats, the concentrations of KRM-1648 in plasma, whole blood, and tissues peaked between 2.0 and 24.0 h, with elimination half-lives ranging from 6.2 to 19.5 h. The peak concentrations and the areas under the concentration-versus-time curves (AUC) for whole blood and tissues were 2 to 277 times higher than those for plasma. The high levels of KRM-1648 in tissues were consistent with its large volume of distribution (in excess of 10 liters/kg). A nonlinear increase in peak concentrations and AUCs for plasma, whole blood, and tissues occurred as the dose was increased and was consistent with the dose-dependent decrease in bioavailability. In the dogs, KRM-1648 levels in plasma and whole blood also exhibited a late time to the peak concentration (ranging from 4.0 to 11.2 h), a long elimination half-life (ranging from 15.2 to 24.0 h), and nonlinear kinetics. KRM-1648 exhibited high levels of plasma protein binding (more than 99%) and a high degree of affinity for lipoproteins in the plasma of both animals. After administration of KRM-1648, measurable levels of its metabolites, 25-deacetyl KRM-1648 in rats and 25-deacetyl KRM-1648 and 30-hydroxy KRM-1648 in dogs, were found in the biological samples tested. Thus, KRM-1648 is characterized by a high tissue affinity, a long elimination half-life, and nonlinear pharmacokinetics.
Several rifamycin derivatives including rifabutin (31) , rifapentine (2) , and CGP-7040 (28) have been reported to be active in vitro against Mycobacterium avium complex, one of the most common causes of bacteremia in patients with AIDS. However, the clinical usefulness of these rifamycins has not been established, with the exception that rifabutin was recently shown to be effective in delaying and offering partial protection against the development of disseminated M. avium complex infection in patients with AIDS (21) .
KRM-1648 [3Ј-hydroxy-5Ј-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin] is a new rifamycin derivative which appears to be highly suitable for use in humans since its activity is superior to those of rifampin and rifabutin against M. avium complex and Mycobacterium tuberculosis in various experimental models in vitro (11, 20, 23, 32) and in vivo (5, 13, 14, 16, 27, 33, 34) .
Our previous studies have shown that KRM-1648 is distributed to a much greater extent in tissues than in plasma, that it has a long elimination half-life in mice (35) , and that it is metabolized via deacetylation at the 25 position and oxidation at the 30 position in dogs (10) . The present paper describes the pharmacokinetics of KRM-1648 and its metabolites in rats and dogs.
(Parts of this study were presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., 17 to 20 October 1993.)
MATERIALS AND METHODS
Chemicals. KRM-1648, 25-deacetyl KRM-1648, and an internal standard [3Ј-hydroxy-5Ј-(4-isopentyl-1-piperazinyl)benzoxazinorifamycin] were synthesized (35) , and 30-hydroxy KRM-1648 was purified from the by-products of KRM-1648 synthesis in our laboratories. All other reagents were of analytical grade.
Animals. Male Crj:CD (Sprague-Dawley) rats weighing 350 to 430 g and male TOYO beagle dogs weighing 9 to 11 kg were used. All animals were administered KRM-1648 under nonfasted conditions, since preliminary studies showed that food intake increases the bioavailability of KRM-1648.
Drug administration and preparation of assay samples. (i) Rats. For kinetic studies, four rats were used for each sampling time point, and each rat received a single oral dose of KRM-1648 at 3, 30, or 100 mg/kg of body weight as a suspension in 2.5% (wt/vol) gum arabic or a single intravenous (i.v.) bolus dose of KRM-1648 at 3 mg/kg as a solution in water containing 5% (vol/vol) ethanol and 0.25% (wt/vol) polyoxyethylene hydrogenated castor oil 60. Blood samples (at least 2 ml) were taken from the abdominal aorta, with the rats under ether anesthesia, at 1, 2, 4, 6, 8, 12, 24, and 48 h after oral administration and at 5, 10, 20, and 40 min and 1, 2, 4, 8, 12, 24, and 48 h after i.v. administration. Tissue samples were obtained from exsanguinated rats at the same times as the blood samples. The tissues were washed in saline, blotted with absorbent paper, and minced on ice. A sample of about 0.2 g was weighed accurately and was stored at Ϫ20ЊC until analysis. Plasma and whole blood samples were stored on ice, and extractions were done within 24 h. For in vivo protein binding studies, two or three rats received a single oral dose of KRM-1648 at 300 mg/kg as a suspension in 2.5% (wt/vol) gum arabic. Plasma was obtained at 12 h after administration.
(ii) Dogs. Five dogs each received KRM-1648 at 3, 30, or 100 mg/kg orally and at 1 mg/kg i.v. (bolus) in a crossover fashion with a washout period of at least 2 weeks between doses. The dosing suspension and solution were prepared as described for the rat study. Blood samples (2 ml) were taken from the cephalic vein at 1, 2, 3, 4, 5, 6, 8, 12, 24, and 48 h after oral administration and at 5, 10, 20, and 40 min and 1, 2, 4, 6, 8, 12, 24, and 48 h after i.v. administration. Plasma and whole blood samples were stored on ice, and extractions were done within 24 h.
Protein binding. The plasma protein binding of KRM-1648 in vitro was examined by equilibrium dialysis with the Side-Bi-Side DC-100B Diffusion Cell (Crown Glass Corp.) with a Spectra POR-2 membrane. KRM-1648 (10 l of KRM-1648 at 1 mg/ml in ethanol) was added to 10 ml of plasma obtained from the intact rats or dogs to obtain a concentration of 1 g/ml, and then the mixture was incubated for 1 h at 37ЊC. A portion (3.4 ml) of the plasma (Donor) was dialyzed for 96 h at 4ЊC against the same volume of normal plasma (Acceptor). Drug levels in the plasma were assayed by high-performance liquid chromatography (HPLC). The degree of binding was calculated as [1 Ϫ (acceptor concentration)/(donor concentration)] ϫ 100, where the acceptor concentration and the donor concentration were the KRM-1648 concentrations in the acceptor and the donor, respectively, after dialysis.
Distribution in lipoproteins.
Rat or dog plasma containing 1 g of KRM-1648 per ml (see above) was separated into fractions of different densities by a density gradient ultracentrifugation procedure described previously (3), with minor modifications. Briefly, a step gradient was constructed from four NaCl-KBr solutions (7.5 ml in total) varying in density from 1.006 to 1.240 g/ml and 2.5 ml of plasma adjusted to 1.21 g/ml in density. After ultracentrifugation (160,000 ϫ g at 15ЊC for 48 h), fractions were collected from the bottoms of the tubes, and the KRM-1648 content was measured by HPLC. The identification of lipoproteins was performed by the measurement of total cholesterol (1), high-density lipoprotein (HDL) cholesterol (12) , phospholipid (24) , triglyceride (26) , and protein (19) levels in the fractions.
Sample analysis. For kinetic studies, plasma (1.0 ml for rats and 0.5 ml for dogs), whole blood (0.4 ml for rats and dogs), and tissue samples (0.2 g) were analyzed for KRM-1648 and two metabolites, 25-deacetyl KRM-1648 and 30-hydroxy KRM-1648, by a reverse-phase HPLC procedure in accordance with the detailed description given in our previous paper (9) , with minor modifications. This method was developed to minimize the interfering effects of the biomatrix. In brief, KRM-1648 and its metabolites were extracted with the internal standard from each sample matrix by using solid-phase extraction cartridges (Bond Elut; Analytichem International). Plasma samples were directly loaded onto C8 Bond Elut cartridges, while whole blood and tissue samples were homogenized, and extractions were done with methanol (whole blood) or dichloromethane-chloroform (1:4; vol/vol) (tissue) prior to SI Bond Elut cartridge extraction. The extracts were reconstituted in methanol and chromatographed on a Shim-pack CLC-ODS(M) column (5 m; 250 by 4.6 mm [inner diameter]; Shimadzu) by using acetonitrile-0.02 M citrate buffer containing 0.1 M sodium perchlorate (pH 4.3; 2:1; vol/vol) at a flow rate of 1.0 ml/min. The eluate was monitored at a wavelength of 643 nm. Standard curves were prepared by assaying each blank sample to which known amounts of analytes and the internal standard had been spiked. Standard curves for plasma were prepared for concentration ranges of 0.01 to 1 g/ml, standard curves for whole blood were prepared for concentration ranges of 0.02 to 10 g/ml for rats and dogs, and standard curves for tissue were prepared for concentration ranges of 0.1 to 30 g/g for rats. Standard curves were obtained by weighted (1/concentration 2 ) least-squares linear regression analysis. All standard curves were linear, with correlation coefficients being greater than 0.990. The lower limits of quantitation for rats were 0.02 g/ml for plasma, 0.04 g/ml for whole blood, and 0.2 g/g for tissues for both KRM-1648 and 25-deacetyl KRM-1648, and those for dogs were 0.02 g/ml for plasma and 0.03 g/ml for whole blood for KRM-1648, 25-deacetyl KRM-1648, and 30-hydroxy KRM-1648.
In protein binding studies, plasma (3.0 ml) or each fraction separated (0.8 ml) was processed for solid-phase extraction. In vitro KRM-1648 concentrations were determined by the external standard method, with corrections made by using recovery of the internal standard. The standard curve was prepared in concentration ranges of 0.002 to 1 g/ml and was linear, with the correlation coefficient being greater than 0.990. The lower limit of quantitation was 0.002 g/ml.
Pharmacokinetic analysis. The following parameters were determined with the nonlinear least-squares computer program PAG-CP, developed by Takebe et al. (25) (Asmedica, Osaka, Japan): the peak concentration observed in plasma, whole blood, and tissues (C max ), the time to C max (T max ), the half-life (t 1/2 ) determined from the elimination rate constant (k el ), as calculated by using linear least-squares regression analysis of the terminal log phase of the concentrationversus-time curve, the area under the concentration-versus-time curve from time zero to infinity (AUC 0-ϱ ) calculated by conventional linear trapezoidal and extrapolation methods from observed points, the area under the concentrationversus-time curve from time zero to the last sampling time point (T) with a quantifiable concentration (AUC 0-T ) calculated by the trapezoidal rule, the systemic clearance (CL) determined from the dose divided by the AUC 0-ϱ , the volume of distribution (V area ) calculated by dividing the dose by the product of k el and the AUC 0-ϱ (7), and the volume of distribution at steady state (V ss ) calculated by the following formula for an i.v. bolus dose: V ss ϭ (dose ϫ AUMC)/ (AUC 0-ϱ ) 2 , where AUMC is the area under the first moment of the plasma AUC 0-ϱ (6) . For the rat study, the mean values for four rats were used for each time point in the pharmacokinetic analysis. For the dog study, the individual drug concentration-versus-time data were used in the analysis. The bioavailability was determined by comparing the plasma AUC 0-ϱ values following oral administration with those after i.v. injection by the following equation:
RESULTS
KRM-1648 levels in plasma, whole blood, and tissues of rats. The concentrations of KRM-1648 in plasma, whole blood, and tissues and their pharmacokinetic parameters for rats given a single oral dose of 3, 30, or 100 mg/kg are presented in Fig. 1 and Table 1 , respectively. The levels of KRM-1648 in tissues were much higher than those in plasma, and the highest values of C max and AUC were found for the liver at the 3-mg/kg dose and for the spleen at the 30-and 100-mg/kg doses. The ratios of the C max and AUC values in the liver to those in plasma at 3 mg/kg were 33 and 59, respectively. The ratios of the C max and AUC values in the spleen to those in plasma at 30 and 100 mg/kg ranged from 196 to 277. In addition, the levels of KRM-1648 in whole blood were higher than those in plasma. The ratios of C max and AUC in whole blood to those in plasma ranged from 2 to 4. The whole blood-toplasma partitions calculated individually for each rat administered 3, 30, or 100 mg/kg were 2.1 Ϯ 0.9 (mean Ϯ standard deviation [SD] ; n ϭ 23), 2.9 Ϯ 1.0 (n ϭ 30), and 3.5 Ϯ 1.1 (n ϭ 35), respectively. A rather late T max ranging from 6 to 24 h and a long t 1/2 ranging from 10.7 to 19.5 h were found for plasma, whole blood, and tissues at doses of 30 and 100 mg/kg, and for liver and spleen at a dose of 3 mg/kg.
The relationship between AUC and dose is illustrated in Fig.  2 . Although the AUCs for plasma, whole blood, and tissues (other than spleen) increased proportionally or more than proportionally (spleen) to the increase in dose between 3 and 30 mg/kg, they increased less than proportionally to the increase in dose between 30 and 100 mg/kg. Similarly, the C max s for plasma, whole blood, and tissues increased less than proportionally to the dose ( Table 1) .
The concentrations of KRM-1648 in plasma, whole blood, and tissues and pharmacokinetic parameters for rats given a single i.v. dose of 3 mg/kg are presented in Fig. 3 and Table 1 . From 5 min after administration, the KRM-1648 levels in plasma, whole blood, lung, and kidney decreased, while KRM levels in the liver and spleen peaked at 20 min and 4 h after Levels of a metabolite of KRM-1648 in plasma, whole blood, and tissues of rats. When KRM-1648 was administered to rats orally at 3, 30, and 100 mg/kg, significant amounts of 25-deacetyl KRM-1648 were detected in all biological samples tested except the plasma and kidney for the 3-mg/kg dose. The concentrations of 25-deacetyl KRM-1648 in plasma, whole blood, and tissues and their pharmacokinetic parameters are presented in Fig. 1 and Table 2 , respectively. This metabolite of KRM-1648 was also characterized by much higher levels in tissues, especially liver and spleen, than in plasma, as was also the case for the parent compound. The ratios of C max values in liver to those in plasma and in spleen to those in plasma obtained with doses of 30 and 100 mg/kg ranged from 67 to 645. The ratios of C max s for the metabolite to that for the parent compound ranged from 4 to 38%, and the ratios of AUCs for the metabolite to that for the parent compound ranged from 13 to 59% for all tissues except for the spleen at the 3-mg/kg dose.
Levels of KRM-1648 in plasma and whole blood of dogs. The concentrations of KRM-1648 and its pharmacokinetic parameters for dogs after the administration of a single oral dose of KRM-1648 at 3, 30, or 100 mg/kg are presented in Fig. 4 and Table 3 , respectively. The results obtained for dogs were similar to those obtained for rats. Rather late T max s ranging from 4.8 to 11.2 for plasma and from 4.0 to 9.4 h for whole blood and long t 1/2 s ranging from 15.2 to 17.5 h for plasma and from 15. 4   FIG. 2 . Relationship between KRM-1648 AUC and dose for plasma, whole blood, and tissues of rats administered KRM-1648 orally at 3, 30, and 100 mg/kg. Each point represents a value calculated by using the mean concentration for four rats. to 24.0 h for whole blood were found. Although AUCs for plasma and whole blood were dose dependent, the increase in either C max or AUC values was less than proportional to the increase in dose (Fig. 5) . In contrast to those for rats, in dogs AUCs for whole blood were comparable to those for plasma.
The whole blood-to-plasma partitions calculated individually for each dog administered 3, 30, or 100 mg/kg were 1.4 Ϯ 0.4 (mean Ϯ SD; n ϭ 45), 1.1 Ϯ 0.2 (n ϭ 50), and 1.2 Ϯ 0.3 (n ϭ 50), respectively. The V area , V ss , and CL of KRM-1648 were 9.1 liters/kg, 9.2 liters/kg, and 0.38 liter/h/kg, respectively, after i.v. administration (Table 3) . Levels of metabolites in plasma and whole blood of dogs. When KRM-1648 was administered to dogs orally at 3, 30, and 100 mg/kg, two metabolites, 25-deacetyl KRM-1648 and 30-hydroxy KRM-1648, were detected in both plasma and whole blood (Fig. 4 and Table 3 ). The C max s and AUCs of 25-deacetyl KRM-1648 in plasma and whole blood were 10 to 30% and 25 to 87% of those of the parent compound, respectively. In the case of 30-hydroxy KRM-1648 in plasma and whole blood, C max s and AUCs were 22 to 55% and 23 to 62% of those of the parent compound, respectively.
Bioavailability in rats and dogs. Bioavailabilities after the administration of single oral doses of 3, 30, and 100 mg/kg were 26.9, 13.0, and 4.7%, respectively, in rats and 42.9, 21.0 and 8.0%, respectively, in dogs (Tables 1 and 3 ). The absolute bioavailability in both animals decreased as the dose was increased.
Plasma protein binding of KRM-1648. The plasma protein binding values for KRM-1648 in rats and dogs are summarized in Table 4 . In the in vitro study, more than 99% of KRM-1648 was bound to plasma protein in both rats and dogs. A similar high rate of binding to plasma protein, 99.5%, was observed in the in vivo study with rats. Plasma lipoprotein binding of KRM-1648. The distribution of KRM-1648 in rat and dog plasma is summarized in Table 5 . In the in vitro study, 92 to 94% of the drug appeared in the lipoprotein fractions (d Ͻ 1.20 [where d is density in grams per milliliter]), while less than 9% was found in the lipoproteindeficient fraction (d Ͼ 1.20) in both rats and dogs. Among the lipoproteins, HDL accounted for most of the plasma lipoprotein binding of KRM-1648. About 70% (in rats) or 90% (in dogs) of KRM-1648 was associated with HDL. A high affinity to HDL (76.9%) was also observed in the in vivo study with rats.
DISCUSSION
The pharmacokinetics of KRM-1648 in rats and dogs after the administration of a single oral dose of KRM-1648 were studied. The results for rats demonstrated the following features of KRM-1648: (i) high levels in tissues, especially liver and spleen; (ii) higher levels in whole blood than in plasma, indicating penetration into blood cells; (iii) rather late T max s, long t 1/2 s, and nonlinear kinetics for plasma, whole blood, and tissues; and (iv) extensive distribution into plasma lipoproteins. In the study with dogs, KRM-1648 also displayed nonlinear kinetics, late T max s, and long t 1/2 s for plasma and whole blood and extensive distribution into plasma lipoproteins. Although the levels of KRM-1648 in the tissues of dogs were not determined in this study, the V ss of KRM-1648 in dogs was greater than 9 liters/kg ( Table 3 etrate into both extracellular and intracellular spaces in dogs. This was confirmed by the findings that the levels of KRM-1648 in lung, liver, kidney, and spleen were 6 to 12 times higher than the corresponding levels in plasma at 28 and 30 h after administration of the last dose of 30 and 100 mg/kg/day, respectively, in a preliminary 4-week, multiple-dose toxicity study in dogs (unpublished data). Although the levels in whole blood were comparable to the levels in plasma for dogs, this still indicates the penetration of KRM-1648 into blood cells. This penetration into blood cells may explain at least in part the high levels of KRM-1648 in the spleen, which contains many blood cells in its red and white pulp (4) .
It is well recognized that the distribution of drugs into tissues requires crossing of the lipid barriers of the cellular membranes, and therefore, the lipophilicities of drugs play a major role in determining the extent of their distribution to organs (17) . The tissue tropism of KRM-1648 could be accounted for by its lipophilicity, since a physicochemical study revealed that KRM-1648 is very lipophilic; the log P value of the octanolwater partition coefficients is 4.81 (unpublished data).
The high degree of lipophilicity of KRM-1648 may also account for its distribution into plasma lipoproteins. Plasma lipoprotein has been observed to interact with large numbers of pharmacological compounds including cyclosporin (18) , probucol (29) , ticlopidin (8), 1,3-bis(2-chloroethyl)-1-nitrosourea (30) , and estradiol (22) . These compounds have the common feature of lipophilicity and are thought to be dissolved in the hydrophobic core of lipoproteins. These findings support the hypothesis that plasma lipoproteins play roles as carriers in the transport of KRM-1648 in the blood. For example, KRM-1648 may be transported to and accumulated in liver in association with HDL, which is processed in the liver.
With an increase in the KRM-1648 dose administered orally, a nonlinear relationship between dose and C max or AUC values in plasma (for rats and dogs), whole blood (for rats and dogs), and tissues (for rats) was observed. The most plausible explanations for the nonlinear kinetics involve the principal mode of absorption from the gastrointestinal tract. The oral bioavailability of KRM-1648 markedly decreased from 26.9 to 4.7% and from 42.9 to 8.0% in rats and dogs, respectively, when the dose was increased from 3 to 100 mg/kg. In a separate study, the oral absorption of KRM-1648 from suspension and solution formulations at 10 mg/kg was compared in dogs (n ϭ 10; crossover study). There was no difference between the plasma AUC 0-48 for the suspension (11.8 Ϯ 3.9 g ⅐ h/ml; mean Ϯ SD) and that for the solution (11.1 Ϯ 2.8 g ⅐ h/ml).
KRM-1648 has a relatively high solubility of more than 2,000 g/ml at pH 2 and a low solubility of less than 0.1 g/ml at greater than pH 5 (unpublished data). These findings suggest that low solubility in water in the intestine is a principal reason for the dose-dependent decrease in the bioavailability of KRM-1648. Since the extent of drug protein binding influences the distribution and elimination of a drug (15) , the saturable binding of KRM-1648 to plasma protein may also explain its nonlinear kinetics.
After the administration of KRM-1648, measurable levels of 25-deacetyl KRM-1648 were observed in plasma, whole blood, and tissues in rats and measurable levels of 25-deacetyl KRM-1648 and 30-hydroxyl KRM-1648 were observed in plasma and whole blood in dogs. These metabolites exhibited pharmacokinetic properties such as tissue tropism (in rats) and long t 1/2 s (in dogs) similar to those of the parent compound. Given these findings and the fact that the in vitro microbiological activities of these metabolites are roughly comparable to that of the parent compound in both potency and bacterial spectrum (10), it appears likely that these metabolites contribute to the excellent in vivo effect of KRM-1648 (5, 13, 14, 16, 27, 33, 34) .
The present study indicates that the pharmacokinetic properties of KRM-1648 are characterized by good tissue penetration, long t 1/2 in plasma, whole blood, and tissues, and a high level of plasma lipoprotein binding, which appears to be attributable to its lipid solubility. The pharmacokinetic characteristics of KRM-1648 suggest that it may be clinically useful for the treatment of bacterial infections caused by intracellular pathogens such as M. tuberculosis, M. avium complex, and Staphylococcus aureus. 
